论文部分内容阅读
１９８５年１月～１９９３年１月收治资料完整的肺癌骨转移病人８５例，其中腺癌３４例，小细胞未分化癌２６例，鳞癌２０例，其它癌５例。骨痛是肺癌骨转移的最主要的表现形式（８１．２％），次之为神经系统症状和病理性骨折。肺癌骨转移与病理类型有关：腺癌最常见（４０．０％），小细胞未分化癌（３０．５％），鳞癌（２３．５％）。骨转移的常见的好发部位依次为肋骨（４８．２％）、胸椎（３９．９％）、腰椎（３５．３％）和骨盆（３１．６％）。病灶以多发转移为主（７８．９％）。放射性核素骨显影对肺癌骨转移的诊断价值优于Ｘ线。肺癌骨转移的治疗以对症治疗和局部治疗为主，对一般情况较好者，可补加特异性治疗．所有病人的平均生存时间为２．７个月。单一与多发二者的生存期分别为３．３个月和２．１个月；局部治疗对生存期也无明显的影响。自确诊后的１年生存率为５．３％，２年生存率为２．１％，３年生存率为０。
From January 1985 to January 1993, 85 patients with complete bone metastases from lung cancer were treated, including 34 adenocarcinomas, 26 undifferentiated small cell carcinomas, 20 squamous cell carcinomas, and 5 other cancers. Bone pain is the main manifestation of bone metastasis in lung cancer (81.2%), followed by neurological symptoms and pathological fractures. Bone metastases from lung cancer were associated with pathological types: adenocarcinomas were most common (40.0%), small cell undifferentiated carcinomas (30.5%), and squamous cell carcinomas (23.5%). The common sites of bone metastases were ribs (48.2%), thoracic vertebrae (39.9%), lumbar vertebrae (35.3%), and pelvis (31.6%). The lesions were dominated by multiple metastases (78.9%). The diagnostic value of radionuclide bone imaging in bone metastasis of lung cancer is better than X-ray. The treatment of lung cancer bone metastases is mainly symptomatic treatment and local treatment. For those who are generally better, specific treatment can be supplemented. The average survival time for all patients was 2.7 months. The survival times of single and multiple were 3.3 months and 2.1 months, respectively; local treatment had no significant effect on survival. The 1-year survival rate after self-diagnosis was 5.3%, the 2-year survival rate was 2.1%, and the 3-year survival rate was 0.